Patent ID: 9234899
Filing Date: 2016-01-12
CPC Classification: C07K,G01N

Claim Text:
1. A method for determining whether a prostate sample from a subject is cancerous, comprising contacting the sample with an antibody against human βV-tubulin, or a fragment thereof capable of binding to human βV-tubulin, wherein the antibody or fragment is directed against an epitope comprising GEEAFEDEEEEIDG (SEQ ID NO:1) or CGEEAFEDEEEEIDG (SEQ ID NO:2), quantitating an amount of antibody or fragment bound, comparing the amount of bound antibody or fragment to a predetermined control amount in healthy prostate tissue, and determining whether the prostate sample is cancerous, wherein the amount of antibody or fragment bound equal to or in excess of the predetermined control amount indicates that the prostate sample is not cancerous, and the amount of antibody or fragment bound below the predetermined control amount indicates that the prostate sample is cancerous.